FDA
-
-
-
-
-
-
-
Clementia Pharmaceuticals Inc. Obtains Interim Order for Proposed Transaction With Ipsen S.A. and Enters Into Support and Voting Agreements With Two Additional Significant Shareholders
-
-
-
-
-
-
-
Clementia (CMTA) Granted Rare Pediatric Disease Designation by FDA for Palovarotene for FOP
-
-
-
-
-
-
-
Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
-
-
-
-
-
-
-
Clementia Announces Proposed Public Offering of Common Shares
-
-
-
-
-
-
-
Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP
-
-
-
-
-
-
-
Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
-
-
-
-
-
-
-
Clementia Reports Third Quarter 2017 Financial Results and Business Highlights
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

